ALPHAMAB-B(09966),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

09966 ALPHAMAB-B

Closed 01-23 16:08:28

9.630

+0.010

+0.10%

High9.870	Low9.400	Vol1.37M
Open9.620	D1 Closing9.620	Amplitude4.89%
Mkt Cap9.33B	Tradable Cap9.33B	Total Shares969.00M
T/O13.20M	T/O Rate0.14%	Tradable Shares969.00M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

Disclaimer: HKEx Information Services Limited, its holding companies and/or any subsidiaries of such holding companies endeavour to ensure the accuracy and reliability of the information provided, but do not guarantee its absolute accuracy and reliability and accept no liability (whether in tort or contract or otherwise) for any loss or damage arising from any inaccuracies or omissions.

{"stockData":{"symbol":"09966","market":"HK","secType":"STK","nameCN":"ALPHAMAB-B","latestPrice":9.63,"timestamp":1769155708006,"preClose":9.62,"halted":0,"volume":1371000,"delay":0,"changeRate":0.001039501039501202,"floatShares":969000000,"shares":969000000,"eps":0.19360184458410984,"marketStatus":"Closed","change":0.01,"latestTime":"01-23 16:08:28","open":9.62,"high":9.87,"low":9.4,"amount":13200930,"amplitude":0.048857,"askPrice":9.63,"askSize":8000,"bidPrice":9.52,"bidSize":1000,"shortable":3,"etf":0,"ttmEps":0.26462409301092454,"tradingStatus":0,"nextMarketStatus":{"tag":"Open","tradingStatus":2,"beginTime":1769391000000},"marketStatusCode":5,"adr":0,"listingDate":1576080000000,"exchange":"SEHK","adjPreClose":9.62,"openAndCloseTimeList":[[1769131800000,1769140800000],[1769144400000,1769155200000]],"volumeRatio":0.798911,"lotSize":1000,"spreadScale":0,"tradeCurrency":"HKD"},"requestUrl":"/m/hq/s/09966/tweets","defaultTab":"tweets","newsList":[{"id":"1138237418","title":"Soochow Securities Maintains \"Buy\" Rating on Alphamab-B (09966), Core Pipeline Products Under Regulatory Review","url":"https://stock-news.laohu8.com/highlight/detail?id=1138237418","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1138237418?lang=en_us&edition=fundamental","pubTime":"2026-01-23 10:42","pubTimestamp":1769136134,"startTime":"0","endTime":"0","summary":"Soochow Securities has issued a research report maintaining a \"Buy\" rating on Alphamab-B (09966). Considering the company has multiple new ADC pipelines expected to complete preclinical R&D by 2025,...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK0028","BK0183","BK0188","BK0012","09966","601555","BK0009","BK0276","BK1161"],"gpt_icon":0},{"id":"2603951436","title":"A Look At Alphamab Oncology (SEHK:9966) Valuation After KN035 Regulatory Milestone In Biliary Tract Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2603951436","media":"Simply Wall St.","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2603951436?lang=en_us&edition=fundamental","pubTime":"2026-01-16 10:51","pubTimestamp":1768531870,"startTime":"0","endTime":"0","summary":"The latest development at Alphamab Oncology (SEHK:9966) involves China’s regulator formally accepting its new drug application for KN035, in combination with Gemcitabine and Oxaliplatin, for first-line treatment of unresectable or metastatic biliary tract cancer.\nSee our latest analysis for Alphamab Oncology.\nAfter the NMPA accepted the KN035 filing, Alphamab Oncology’s HK$10.28 share price sits alongside a 1-year total shareholder return of 216.31%, while the 90-day share price return of a...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/a-look-at-alphamab-oncology-sehk9966-valuation-after-kn035-r","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/a-look-at-alphamab-oncology-sehk9966-valuation-after-kn035-r","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1574","09966","BK1161","DCF"],"gpt_icon":0},{"id":"2602670965","title":"Alphamab Oncology's KN035 Accepted For Chinese Regulatory Review","url":"https://stock-news.laohu8.com/highlight/detail?id=2602670965","media":"MT Newswires Live","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602670965?lang=en_us&edition=fundamental","pubTime":"2026-01-12 11:50","pubTimestamp":1768189801,"startTime":"0","endTime":"0","summary":"Alphamab Oncology  said Chinese regulators accepted its KN035 combination therapy for review, according to a Hong Kong bourse filing Friday.Shares of the cancer therapy developer fell over 3% in late morning trade on Monday.The firm is seeking approval for KN035 in combination with chemotherapy drugs gemcitabine and oxaliplatin as a first-line treatment of unresectable or metastatic biliary tract cancer.KN035 is also known as envafolimab and Enweida.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK1161","BK1574","09966"],"gpt_icon":0},{"id":"2602300928","title":"Is Alphamab Oncology (SEHK:9966) Quietly Reframing Its Immuno-Oncology Edge With JSKN033’s Phase II IND?","url":"https://stock-news.laohu8.com/highlight/detail?id=2602300928","media":"Simply Wall St.","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602300928?lang=en_us&edition=fundamental","pubTime":"2026-01-10 04:28","pubTimestamp":1767990527,"startTime":"0","endTime":"0","summary":"In late 2025, Alphamab Oncology’s board announced that China’s Center for Drug Evaluation had accepted its Investigational New Drug application for a phase II trial of JSKN033, a high-concentration subcutaneous co-formulation combining a HER2-targeting bispecific ADC and a PD-L1 inhibitor with platinum-based chemotherapy, with or without bevacizumab, in advanced cervical cancer.\nThis acceptance marks a key progression in Alphamab Oncology’s immuno-oncology pipeline, highlighting its effort...","market":"us","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/is-alphamab-oncology-sehk9966-quietly-reframing-its-immuno-o","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/is-alphamab-oncology-sehk9966-quietly-reframing-its-immuno-o","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","BK1574","09966","IND"],"gpt_icon":0},{"id":"2602597377","title":"BRIEF-Alphamab Oncology Says NMPA Accepts NDA For Kn035 First-Line BTC Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2602597377","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602597377?lang=en_us&edition=fundamental","pubTime":"2026-01-09 23:28","pubTimestamp":1767972491,"startTime":"0","endTime":"0","summary":"BRIEF-Alphamab Oncology Says NMPA Accepts NDA For Kn035 First-Line BTC TreatmentJan 9 (Reuters) - Alphamab Oncology 9966.HK:NMPA ACCEPTS NDA FOR KN035 FIRST-LINE BTC TREATMENTFurther company coverage: 9966.HK ((Reuters.Briefs@thomsonreuters.com;))","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nFWN3Y91GL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09966","BK1574"],"gpt_icon":0},{"id":"1129139731","title":"ALPHAMAB-B (09966): NDA for KN035 as First-line BTC Treatment Accepted by NMPA","url":"https://stock-news.laohu8.com/highlight/detail?id=1129139731","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129139731?lang=en_us&edition=fundamental","pubTime":"2026-01-09 22:18","pubTimestamp":1767968298,"startTime":"0","endTime":"0","summary":"ALPHAMAB-B (09966) announced that China's National Medical Products Administration has formally accepted the New Drug Application for KN035 (Envafolimab Injection, brand name: ENVYDA®) in combination...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09966","BK1161","BTC","XBTmain","BTCmain"],"gpt_icon":0},{"id":"2602371237","title":"China NMPA Accepts Alphamab Oncology NDA for KN035 in First-Line Biliary Tract Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2602371237","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602371237?lang=en_us&edition=fundamental","pubTime":"2026-01-09 22:16","pubTimestamp":1767968163,"startTime":"0","endTime":"0","summary":"Alphamab Oncology announced that the National Medical Products Administration  of China has formally accepted the new drug application  for KN035  in combination with the GEMOX regimen for the first-line treatment of unresectable or metastatic biliary tract cancer . The acceptance is based on results from a Phase III clinical trial  evaluating the efficacy and safety of this combination in Chinese patients with advanced BTC. The company cautioned that there is no guarantee of successful approval for this new indication.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on Jan","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nNDL1gVv5Q:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1574","BK1161"],"gpt_icon":0},{"id":"2602371269","title":"Alphamab Oncology - Nmpa Accepts Nda for Kn035 First-Line BTC Treatment","url":"https://stock-news.laohu8.com/highlight/detail?id=2602371269","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602371269?lang=en_us&edition=fundamental","pubTime":"2026-01-09 22:15","pubTimestamp":1767968101,"startTime":"0","endTime":"0","summary":null,"market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260109:nFWN3Y91GL:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","09966","BK1161"],"gpt_icon":0},{"id":"2602311623","title":"Alphamab Oncology (SEHK:9966) Valuation Check After JSKN033 Phase II Trial Clearance In China","url":"https://stock-news.laohu8.com/highlight/detail?id=2602311623","media":"Simply Wall St.","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2602311623?lang=en_us&edition=fundamental","pubTime":"2026-01-09 02:39","pubTimestamp":1767897569,"startTime":"0","endTime":"0","summary":"Regulatory milestone and why it matters for Alphamab Oncology\nAlphamab Oncology (SEHK:9966) has drawn attention after regulators in China accepted its investigational new drug application for a phase II trial of JSKN033 in first line advanced cervical cancer.\nThe open label, multicenter study will test a high concentration subcutaneous co formulation. It combines a HER2 bispecific antibody drug conjugate with a PD L1 inhibitor, alongside platinum based chemotherapy with or without...","market":"sg","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/alphamab-oncology-sehk9966-valuation-check-after-jskn033-pha","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/alphamab-oncology-sehk9966-valuation-check-after-jskn033-pha","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK1161","09966","DCF","BK1574"],"gpt_icon":0},{"id":"1129360197","title":"Hong Kong Stock Movement | ALPHAMAB-B (09966) Surges Over 6% as Phase II Clinical Trial IND Application for JSKN033 Gets Accepted","url":"https://stock-news.laohu8.com/highlight/detail?id=1129360197","media":"Stock News","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1129360197?lang=en_us&edition=fundamental","pubTime":"2026-01-08 10:16","pubTimestamp":1767838597,"startTime":"0","endTime":"0","summary":"ALPHAMAB-B (09966) rose more than 6%, and as of the time of writing, it was up 6.76% to HK$10.89, with a turnover of HK$10.4175 million. Recently, ALPHAMAB-B announced that the Investigational New...","market":"sg","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","IND","BK1161","BK1574"],"gpt_icon":0},{"id":"1174407833","title":"Zhixiang Hong Kong Stock Repurchase Statistics | January 1","url":"https://stock-news.laohu8.com/highlight/detail?id=1174407833","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1174407833?lang=en_us&edition=fundamental","pubTime":"2026-01-01 09:13","pubTimestamp":1767230019,"startTime":"0","endTime":"0","summary":"A total of 58 companies conducted share buybacks on December 31, 2025. Among them, TENCENT (00700) executed the largest buyback by value, repurchasing 1.061 million shares for HK$635 million. The...","market":"fut","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0819121731.USD","LU0708995153.HKD","LU0235996351.USD","LU2778985437.USD","LU0823041008.USD","LU0823413660.USD","LU1051768304.USD","LU0264606111.USD","LU0320764599.SGD","LU0441854154.USD","BK1607","BK1233","BK1521","LU0543330566.HKD","LU0873338254.USD","02586","LU0611395673.USD","LU0979878070.USD","IE0031814852.USD","LU0675040207.SGD","SG9999017495.SGD","LU0516423174.USD","LU0107464264.USD","LU0269904917.USD","LU0127658192.USD","IE0008369823.USD","HXXD.SI","LU1719994722.HKD","09886","LU0633140560.USD","LU0054237671.USD","LU2317271919.USD","LU0348816934.USD","BK1258","SG9999004220.SGD","LU2023250504.SGD","LU1720050803.USD","LU0329678337.USD","LU0856984785.SGD","LU0878005551.USD","LU1048484197.HKD","LU0455707207.USD","SG9999000459.SGD","LU0577902454.USD","09922","06100","LU0784639295.USD","LU1046422090.SGD","BK1615","01995","LU2242644610.SGD","LU1831875114.USD","LU0070217475.USD","LU0348735423.USD","LU1282648689.USD","BK1517","LU0417516738.SGD","LU0828238088.HKD","LU0823039010.USD","LU2399975544.HKD","SG9999015952.SGD","02391","BK1500","LU0577902538.SGD","02678","LU0588545730.USD","LU3063872942.SGD","HTCD.SI","LU0828237510.HKD","02038","LU1642822792.SGD","BK1144","LU0143863198.USD","LU0181495838.USD","LU2051468812.USD","LU1880383440.USD","SG9999014906.USD","LU2177674079.SGD","BK1608","LU2008162690.USD","LU0359201885.HKD","BK1583","LU0054450605.USD","BK1610","LU1152091168.USD","LU1226287875.USD","01516","06868","LU0163747925.USD","LU0541502299.USD","BK1100","LU0314109678.HKD","LU2362541513.USD","03798","IE0032834883.USD","02866","IE00B031HY20.USD","BK1508","LU1282651048.USD","LU0449515922.USD","LU0865486749.SGD","LU1008478684.HKD","LU0868486357.SGD","IE00B3M56506.USD","LU1733274390.USD","SG9999015945.SGD","02652","LU0831103253.SGD","02018","LU1504937902.USD","LU1044876610.USD","LU0345776255.USD","LU1242518931.SGD","LU1769817179.HKD","LU0011963245.USD","LU0320764755.SGD","BK1095","LU1282649810.SGD","LU1718418525.SGD","LU0823397103.USD","LU2125910500.SGD","LU0327786744.USD","SG9999001093.SGD","LU0348788117.USD","LU0348827113.USD","LU1224444064.USD","BK1221","IE0008368411.USD","LU2045819591.USD","LU0594300419.USD","LU1196710864.SGD","LU1956131251.USD","BK1590","BK1526","LU0287142896.SGD","LU0214875030.USD","BK1183","LU0251144936.SGD","06098","LU1044875133.USD","LU2097828714.EUR","BK1504","BK1132","LU1188198961.HKD","LU0821914370.USD","01458","LU0708995583.HKD","LU0972618739.USD","LU1733274473.HKD","IE00B0JY6N72.USD","LU1316542783.SGD","LU1808992512.USD","SGXZ51526630.SGD","LU0469268626.HKD","02142","SG9999000418.SGD","01810","06609","BK1116","SG9999018857.SGD","LU0414403682.SGD","LU0106959298.USD","SG9999001846.SGD","01274","LU0786609619.USD","LU0823413587.USD","LU2362541273.HKD","BK1566","SG9999001069.SGD","LU0164872284.USD","SG9999000327.SGD","LU0320764243.SGD","BK1215","LU0588545904.SGD","IE0032431581.USD","LU1235295612.USD","LU0345769128.USD","IE00B0169N27.USD","LU0890818403.SGD","LU0862451837.USD","LU2152927971.USD","LU0203347892.USD","02509","LU1439102457.SGD","LU1226288170.HKD","LU0348783662.USD","LU1785774172.SGD","09959","BK1585","IE0001KFT4U8.USD","LU0607220059.USD","BK1591","LU0164865239.USD","LU0502904849.HKD","LU0348767384.USD","LU0572940350.SGD","LU1044874839.SGD","02886","LU1481107354.HKD","LU0128522744.USD","LU1048596156.SGD","01024","SGXZ90724238.SGD","LU1770036033.HKD","SGXZ81514606.USD","IE00B97KM107.HKD","SG9999007991.SGD","01672","LU2106854487.HKD","LU0499858602.USD","LU0210526637.USD","LU0128522157.USD","LU0516422366.SGD","LU0886674414.USD","LU0029874905.USD","02869","02517","LU0633140727.USD","IE0003851619.USD","LU0823038988.USD","LU0417516571.SGD","BK1229","IE0003895053.USD","LU0048580855.USD","09878","LU1993786604.SGD","LU1282649141.HKD","LU0067412154.USD","06608","02598","LU0456846285.SGD","LU1023057109.AUD","LU0871576103.HKD","LU1048588211.SGD","BK1124","SG9999014898.SGD","LU2097828631.EUR","BK1105","LU0049112450.USD","IE00BQXX3F31.USD","BK1109","LU0608807946.USD","LU2237443978.SGD","BK1523","02621","LU0828237940.HKD","LU0051755006.USD","LU1328615791.USD","LU1794554557.SGD","LU1655091459.SGD","SG9999006514.SGD","LU0254981946.USD","LU1814569148.SGD","01868","BK1117","LU0516422952.EUR","LU0348805143.USD","BK1142","SG9999014880.SGD","BK1191","LU0315178854.USD","LU0449509016.USD","LU2462611646.USD","LU1102505762.USD","LU0737861699.HKD","02219","LU0531971595.HKD","BK1604","LU1439103000.SGD","LU1675838814.USD","BK1167","02419","LU0456827905.SGD","LU2265009873.SGD","IE00B5MMRT66.SGD","02416","LU0672654166.SGD","09857","LU0516423091.SGD","LU0737861772.HKD","BK1195","LU1981816686.USD","BK1518","LU0231483743.USD","BK1586","81810","IE00B8HQ1Z84.USD","LU0307460666.USD","IE00B543WZ88.USD","LU1303224171.USD","LU0738912210.USD","LU2251237306.USD","LU1226287792.SGD","LU2293587155.HKD","LU1868837722.USD","LU0882747503.HKD","LU0192582467.USD","LU0577902611.USD","LU2097828474.EUR","SG9999002828.SGD","LU0540923850.HKD","LU1725190679.HKD","LU0651946864.USD","BK1589","IE0009570106.USD","SG9999002463.SGD","LU0132412106.USD","BK1516","LU1883866441.USD","LU0918141887.USD","00909","LU0348766576.USD","LU1323998911.USD","IE00BZ08YR35.GBP","LU2362540622.SGD","LU0823040885.USD","BK1619","BK1249","LU2449936058.SGD","LU1051769294.HKD","LU1807302812.USD","LU1917777945.USD","01600","LU1960683339.HKD","HK0000320223.HKD","LU0348783233.USD","LU0819123356.HKD","LU2226246903.HKD","SG9999001689.USD","IE00BPRC5H50.USD","81024","IE00B067MR52.USD","LU0164880469.USD","LU0509642566.USD","LU1152091754.HKD","09966","LU0048597586.USD","LU1211504680.USD","LU0700851271.USD","LU0797268264.HKD","00314","LU0345769631.USD","LU0169518387.USD","LU0359201612.USD","LU0608807433.USD","SG9999015986.USD","LU2460026573.USD","LU0985320562.USD","LU0516422440.USD","LU0072913022.USD","LU0210533765.USD","SG9999001051.SGD","BK1155","LU0173614495.USD","00700","LU0149721374.USD","LU0499858438.USD","08017","09896","LU0293314216.USD","LU0463099449.HKD","BK1161","LU2087589342.USD","LU0593848301.USD","LU2237443549.SGD","LU2476274720.SGD","LU2251237488.HKD","LU0359202008.SGD","BK1104","BK1209","LU0326948709.USD","01651","SG9999006597.SGD","HK0000320264.USD","BK1128","BK1535","SG9999015978.USD","09669","LU1196710195.USD","SG9999014914.USD","LU0648948544.HKD","LU0117844026.USD","LU1804176565.USD","LU0096374516.USD","BK1618","LU0348723411.USD","LU1629966141.USD","LU0029875118.USD","BK1515","LU0589944569.HKD","LU1961090484.USD","IE00BF5LJ272.USD","LU0228659784.USD","LU1282651121.HKD","LU2257852520.SGD","LU2133065610.SGD","IE0034224299.USD","LU2279701549.SGD","IE00B031J352.USD","LU0348825331.USD","LU0577902371.SGD","LU2498475776.HKD","BK1131","LU0117841782.USD","BK1609","LU0049853897.USD","LU0188438112.USD","LU0823397285.USD","06078","LU0384037296.USD","LU1515016050.SGD","LU1951186391.HKD","SG9999001226.SGD","IE00BZ08YT58.USD","LU1102505929.USD","IE00B8L5B284.USD","BK1587","LU0196878994.USD","LU0143863784.USD","LU0345775950.USD","LU1734074674.USD","LU0228367735.SGD","LU0052750758.USD","SG9999002562.SGD","LU0084288322.USD","LU1242518857.USD","LU2237443895.HKD","03650","IE00B031HW06.USD","LU0165289439.USD","IE00BQXX3D17.EUR","LU1226288253.USD","LU0634319403.HKD","LU1366334578.USD","LU0244354667.USD","SG9999018865.SGD","LU0259732245.USD","BK1253","IE00BZ08YS42.EUR","LU1226288097.SGD","BK1542","LU0149534421.HKD","LU0328353924.USD","LU0080751232.USD","LU2247934214.USD","LU0642271901.SGD","BK1574","TCHmain","LU0261950983.USD","LU1224709979.USD","02299","02121","LU1226287529.USD","IE0003795394.USD","HK0000306701.USD","LU2237443465.HKD","BK1531","LU0880133367.SGD","SGXZ31699556.SGD","LU0588545490.SGD","LU0326950275.SGD","LU1770034418.SGD","SG9999003461.SGD","LU0501845795.SGD","IE00BGV7N243.SGD","LU0791591158.USD","LU0175139822.USD","LU0488056044.USD","LU0047713382.USD","LU1105468828.SGD","06831","IE0008368742.USD","LU2488822045.USD","SG9999014674.SGD","IE00B0169L03.USD","GB00BDT5M118.USD","BK1160","IE00BQXX3C00.GBP","LU0683595622.HKD","LU0862451753.SGD","LU0543330483.HKD","BK1575","HK0000252152.HKD","LU0651947912.USD","LU0791590937.USD","LU0588546209.SGD","BK1193","LU0210527791.USD","SG9999013353.USD","LU0211977185.USD","LU0048388663.USD","LU0431992006.USD","LU0211331839.USD","LU1568876335.HKD","LU0289960550.SGD","LU0348814723.USD","SG9999001903.USD","LU0823426308.USD","LU0261947096.USD","LU1880383366.USD","LU0561508036.HKD","01588","06887","BK1613","LU0140636845.USD","LU1251922891.USD","LU1769817096.USD","LU1810669033.SGD","LU0417516902.SGD","LU0039217434.USD","LU1974910355.USD","LU0823426480.USD","XIACY","LU0370786039.SGD","HK0000252160.HKD","01897","LU0061477393.USD","LU0898667661.SGD","LU2125910849.SGD","LU0531970944.HKD","LU0594300179.USD","LU0329678170.USD","LU1366334651.USD","LU0348784397.USD","LU0572939691.SGD","HK0000306685.HKD","LU1868837565.USD","LU2097828805.USD","BK1246","LU2039709279.SGD","LU2097828557.USD","LU0572944931.SGD","LU0456842615.SGD","LU1328277881.USD","LU1568876251.USD","HK0000165453.HKD","LU2237443382.USD","LU1688375341.USD","LU0106259558.USD","LU0203345920.USD","LU0541501648.USD","LU0229945570.USD","LU1282649067.USD","IE00B29SXG58.USD","LU0605514214.HKD","LU0072462343.USD","00345","LU0106252389.USD","LU0878004406.USD","LU0043850808.USD","LU2476274308.USD","LU1813983027.USD","SGXZ99366536.SGD","LU1868838027.USD","LU1196710351.USD","BK1247","BK1506","LU0650527681.SGD","BK1237","LU2237443622.USD","BK1502","LU0918141705.HKD","HK0000500386.USD","BK1549","LU0396098781.USD","LU0577902298.EUR"],"gpt_icon":1},{"id":"1152610011","title":"ALPHAMAB-B (09966) Spends HK$4.8335 Million on December 31 to Repurchase 500,000 Shares","url":"https://stock-news.laohu8.com/highlight/detail?id=1152610011","media":"Stock News","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1152610011?lang=en_us&edition=fundamental","pubTime":"2025-12-31 17:13","pubTimestamp":1767172408,"startTime":"0","endTime":"0","summary":"ALPHAMAB-B (09966) announced that on December 31, 2025, it expended HK$4.8335 million to repurchase 500,000 of its own shares.","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09966","BK1574"],"gpt_icon":0},{"id":"2595722276","title":"Alphamab Oncology Files HKEX Disclosure on 500,000 Share Repurchase at HKD 4.83 Million","url":"https://stock-news.laohu8.com/highlight/detail?id=2595722276","media":"Reuters","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595722276?lang=en_us&edition=fundamental","pubTime":"2025-12-31 16:57","pubTimestamp":1767171473,"startTime":"0","endTime":"0","summary":"Alphamab Oncology has filed a next day disclosure return with the Hong Kong Stock Exchange, reporting the repurchase of 500,000 shares at a total aggregate price of HKD 4,833,510. The repurchased shares are being held as treasury shares.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate this news brief via IIS, the Issuer Information Service operated by the Hong Kong Stock Exchange  , on December 31, 2025, and is solely responsible for the information contained therein.","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251231:nNDL7dVmhB:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","09966","BK1574"],"gpt_icon":0},{"id":"1181201856","title":"Alphamab-B (09966): Phase II Clinical Trial IND Application for JSKN033 Officially Accepted by CDE","url":"https://stock-news.laohu8.com/highlight/detail?id=1181201856","media":"Stock News","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1181201856?lang=en_us&edition=fundamental","pubTime":"2025-12-29 12:20","pubTimestamp":1766982019,"startTime":"0","endTime":"0","summary":"Alphamab-B (09966) announced that the Investigational New Drug (IND) application for a Phase II clinical trial (Study Number: JSKN033-202) of JSKN033 has been officially accepted by the Center for...","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4017","BK1574","BK1161","LU1223083913.SGD","IND","LU1223082196.USD","CDE","09966","LU1223082519.USD"],"gpt_icon":0},{"id":"2595798206","title":"Alphamab Oncology Wins CDE Approval for Phase II JSKN033 Cervical Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2595798206","media":"Reuters","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595798206?lang=en_us&edition=fundamental","pubTime":"2025-12-29 12:11","pubTimestamp":1766981500,"startTime":"0","endTime":"0","summary":"Alphamab Oncology announced that its Investigational New Drug  application for a phase II clinical trial of JSKN033 has been officially accepted by the Center for Drug Evaluation . The trial will evaluate JSKN033, a high-concentration subcutaneous co-formulation of an anti-HER2 bispecific antibody-drug conjugate and a PD-L1 immune checkpoint inhibitor, in combination with platinum-based chemotherapy with or without bevacizumab as a first-line treatment for advanced cervical cancer. The company cautioned that successful development or marketing of JSKN033 is not guaranteed. No other beneficiary organizations were mentioned.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Alphamab Oncology published the original content used to generate t","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nNDL3VT9Lk:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["09966","BK1574","BK1161"],"gpt_icon":0},{"id":"2595794206","title":"Alphamab Oncology - Ind Application for Jskn033 Phase Ii Trial Accepted by Cde","url":"https://stock-news.laohu8.com/highlight/detail?id=2595794206","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2595794206?lang=en_us&edition=fundamental","pubTime":"2025-12-29 12:11","pubTimestamp":1766981488,"startTime":"0","endTime":"0","summary":null,"market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251229:nFWN3XX03D:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK1574","BK1161","09966"],"gpt_icon":0},{"id":"1117789066","title":"Guojin Securities Initiates Coverage on ALPHAMAB-B (09966) with \"Buy\" Rating, Target Price HK$14.30","url":"https://stock-news.laohu8.com/highlight/detail?id=1117789066","media":"Stock News","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1117789066?lang=en_us&edition=fundamental","pubTime":"2025-12-22 10:08","pubTimestamp":1766369307,"startTime":"0","endTime":"0","summary":"Guojin Securities released a research report forecasting ALPHAMAB-B's (09966) revenue for 2025/2026/2027 at RMB443 million/RMB486 million/RMB550 million, representing year-on-year changes of...","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09966","BK1161"],"gpt_icon":0},{"id":"2592149879","title":"Alphamab Oncology (SEHK:9966): Assessing Valuation After New Breakthrough Therapy and IND Milestones","url":"https://stock-news.laohu8.com/highlight/detail?id=2592149879","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592149879?lang=en_us&edition=fundamental","pubTime":"2025-12-20 21:13","pubTimestamp":1766236431,"startTime":"0","endTime":"0","summary":"Alphamab Oncology (SEHK:9966) just cleared two important regulatory hurdles, with US breakthrough therapy status for JSKN003 and China IND acceptance for JSKN027, tightening investor focus on how these ADC assets might reshape its valuation.\nSee our latest analysis for Alphamab Oncology.\nThe latest catalysts come after a powerful run, with the share price last closing at HK$10.91 and a year to date share price return of 218.08 percent. The 5 year total shareholder return of negative 27.56...","market":"hk","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/alphamab-oncology-sehk9966-assessing-valuation-after-new-bre","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/alphamab-oncology-sehk9966-assessing-valuation-after-new-bre","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["IND","BK1574","DCF","BK1161","09966"],"gpt_icon":0},{"id":"2592932121","title":"What Alphamab Oncology (SEHK:9966)'s IND Acceptance for JSKN027 Bispecific ADC Means For Shareholders","url":"https://stock-news.laohu8.com/highlight/detail?id=2592932121","media":"Simply Wall St.","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592932121?lang=en_us&edition=fundamental","pubTime":"2025-12-19 19:18","pubTimestamp":1766143124,"startTime":"0","endTime":"0","summary":"Alphamab Oncology recently reported that the Center for Drug Evaluation of China’s NMPA has accepted its IND application for JSKN027, an independently developed bispecific antibody-drug conjugate targeting PD-L1 and VEGFR2, paving the way for a Phase I trial in advanced solid tumors.\nThis milestone highlights Alphamab Oncology’s push into next-generation bispecific ADCs that combine immune checkpoint blockade and anti-angiogenic mechanisms within a single molecule.\nWe’ll now examine how the...","market":"nz","thumbnail":"https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552","type":0,"news_type":0,"thumbnails":["https://images.simplywall.st/asset/industry/6111000-choice2-main-header/1585186599552"],"rights":{"source":"simplywall_highlight","url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/what-alphamab-oncology-sehk9966s-ind-acceptance-for-jskn027","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://simplywall.st/stocks/hk/pharmaceuticals-biotech/hkg-9966/alphamab-oncology-shares/news/what-alphamab-oncology-sehk9966s-ind-acceptance-for-jskn027","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"simplywall_highlight","symbols":["BK4080","BK4231","09966","IND","BK1161","BK1574","ADC"],"gpt_icon":0},{"id":"2592924931","title":"BUZZ-Alphamab Oncology jumps on progress of ovarian cancer drug","url":"https://stock-news.laohu8.com/highlight/detail?id=2592924931","media":"Reuters","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2592924931?lang=en_us&edition=fundamental","pubTime":"2025-12-18 13:37","pubTimestamp":1766036264,"startTime":"0","endTime":"0","summary":"BUZZ-Alphamab Oncology jumps on progress of ovarian cancer drug** Alphamab Oncology 9966.HK rises 7.1% to HK$10.96; set for biggest one-day pct gain since October 2** Stock hits highest since December 15 after three straight sessions of fall** Company says its JSKN003 has been granted breakthrough therapy designation  by U.S. FDA to treat adults with advanced or metastatic platinum-resistant recurrent epithelial ovarian cancer** Adds, \"The grant of this BTD further demonstrates the international regulatory community's confidence in JSKN003's clinical potential and its importance as a novel therapeutic candidate\"** Grant of BTD based on pooled analysis of phase I clinical study in Australia and phase I/II clinical study in China** YTD, stock surges 207.1%  ","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20251218:nL1N3XO05J:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","BK1161","09966"],"gpt_icon":0}],"profile":{"websiteUrl":"http://www.alphamab.com","stockEarnings":[{"period":"1week","weight":-0.0642},{"period":"1month","weight":-0.1441},{"period":"3month","weight":-0.1875},{"period":"6month","weight":0.0525},{"period":"1year","weight":1.8378},{"period":"ytd","weight":-0.0184}],"compareEarnings":[{"period":"1week","weight":-0.0109},{"period":"1month","weight":0.0332},{"period":"3month","weight":0.018},{"period":"6month","weight":0.0489},{"period":"1year","weight":0.3464},{"period":"ytd","weight":0.039}],"compareStock":{"symbol":"HSI","name":"HSI"},"description":"Alphamab Oncology is an investment holding company principally engaged in research and development, manufacturing and commercialisation of biologics of oncology. The Company’s highly differentiated in-house pipeline consists of ADCs, monoclonal antibodies and bispecific antibodies in staggered development status in oncology. The Company’s drug candidates include KN046 (PD-L1/CTLA-4 bispecific antibody), KN026 (HER2/HER2 bispecific antibody), KN035 (SubQ PD-L1), JSKN003 (HER2 biparatopic ADC), and others, used for indications such as 1L sq NSCLC, 1L HER2+ BC, advanced solid tumors, and HER2-expressing solid tumors.","yearOnYearQuotes":[{"month":1,"riseRate":0.142857,"avgChangeRate":-0.106963},{"month":2,"riseRate":0.666667,"avgChangeRate":0.22886},{"month":3,"riseRate":0.166667,"avgChangeRate":-0.028638},{"month":4,"riseRate":0.833333,"avgChangeRate":0.061128},{"month":5,"riseRate":0.5,"avgChangeRate":-0.016858},{"month":6,"riseRate":0.333333,"avgChangeRate":-0.029877},{"month":7,"riseRate":0.333333,"avgChangeRate":0.059359},{"month":8,"riseRate":0.333333,"avgChangeRate":0.022561},{"month":9,"riseRate":0.333333,"avgChangeRate":0.158319},{"month":10,"riseRate":0.333333,"avgChangeRate":-0.030396},{"month":11,"riseRate":0.5,"avgChangeRate":0.042537},{"month":12,"riseRate":0.5,"avgChangeRate":-0.017716}],"exchange":"SEHK","name":"ALPHAMAB-B","nameEN":"ALPHAMAB-B"},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.0","shortVersion":"4.36.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"ALPHAMAB-B(09966),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest ALPHAMAB-B(09966) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"ALPHAMAB-B,09966,ALPHAMAB-B股票,ALPHAMAB-B股票老虎,ALPHAMAB-B股票老虎国际,ALPHAMAB-B行情,ALPHAMAB-B股票行情,ALPHAMAB-B股价,ALPHAMAB-B股市,ALPHAMAB-B股票价格,ALPHAMAB-B股票交易,ALPHAMAB-B股票购买,ALPHAMAB-B股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"ALPHAMAB-B(09966),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest ALPHAMAB-B(09966) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}